The role of lipid droplets in metabolic disease in rodents and humans

Andrew S. Greenberg,1 Rosalind A. Coleman,2 Fredric B. Kraemer,3 James L. McManaman,4 Martin S. Obin,1 Vishwajeet Puri,5 Qing-Wu Yan,1 Hideaki Miyoshi,6 and Douglas G. Mashek7

1 Obesity and Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, USA. 2 Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 3 Division of Endocrinology, Stanford University; VA Palo Alto Health Care System, Palo Alto, California, USA. 4 Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado, Anschutz Medical Campus, Denver, Colorado, USA. 5 Department of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, Massachusetts, USA. 6 Department of Internal Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 7 Department of Food Science and Nutrition, University of Minnesota, St. Paul, Minnesota, USA.

Lipid droplets (LDs) are intracellular organelles that store neutral lipids within cells. Over the last two decades there has been a dramatic growth in our understanding of LD biology and, in parallel, our understanding of the role of LDs in health and disease. In its simplest form, the LD regulates the storage and hydrolysis of neutral lipids, including triacylglycerol and/or cholesterol esters. It is becoming increasingly evident that alterations in the regulation of LD physiology and metabolism influence the risk of developing metabolic diseases such as diabetes. In this review we provide an update on the role of LD-associated proteins and LDs in metabolic disease.

Overview of lipid droplets

Lipid droplets (LDs) are intracellular organelles that store neutral lipids within cells. Over the last two decades there has been a dramatic growth in our understanding of LD biology and, in parallel, our understanding of the role they play in health and disease. LDs regulate the storage and hydrolysis of neutral lipids, including triacylglycerol (TAG) and/or cholesterol esters. For example, adipocytes, the major reservoir of TAG in the body, store their TAG within LDs, and TAG storage in adipocytes is increased in obese animals and humans. The rates of adipocyte lipolysis in many obese individuals are constitutively increased, resulting in elevated levels of circulating fatty acids, which may be stored as TAG in LDs within skeletal muscle and liver. Both local and circulating free fatty acids are thought to be important etiologic agents in the development of insulin resistance, hyperlipidemia, inflammation, and hepatic steatosis (1–3). In this article, we will briefly review the basic characteristics of LDs and then focus on our present knowledge of the current view of the role of LDs in metabolic disease.

Cells have developed the capacity to store fatty acids as neutral lipids within LDs for several reasons. An important role of LDs in adipocytes is to store fatty acids as TAG to serve as a reservoir of energetic substrates that can be released when food is scarce. The detrimental effects associated with excess fatty acid entry into cells are often termed “lipotoxicity.” Cells protect themselves from these effects by either oxidizing the fatty acids or sequestering them as TAG within LDs. Consistent with this hypothesis, activation of PPARα, which increases the expression of genes that encode oxidative proteins, also increases the expression of LDs and LD-associated proteins (4, 5). PPARγ and PPARβ, along with other transcription factors, can also promote droplet formation (4, 6). As noted above, when fatty acids exceed the oxidative capacity of cells, they not only enhance LD formation, but may also induce apoptosis. An example of the protection LD formation provides was demonstrated in an experiment in which exogenous oleic acid added to fibroblasts deficient in diacylglycerol acyltransferase 1 (DGAT1) promoted lipotoxic cell death. Expression of DGAT1, the terminal step in TAG synthesis, in fibroblasts channeled excess fatty acids into TAG and LD formation and protected against cell death (7).

The ability to store TAG in LDs is evolutionarily conserved and observed in yeast, plants, invertebrates, and vertebrates (8). The biogenesis and regulation of LDs is an area of intense research interest and is well reviewed elsewhere (9–11). The enzymes involved in TAG biogenesis are located primarily in the endoplasmic reticulum, mitochondria, and related organelles (12, 13). It has been suggested that the TAG of the nascent LD forms a lens within the hydrophobic environment of the ER bilayer (14–16). However, it should be noted that there are several conflicting theories about how the droplets form (17). Ultimately, the TAG droplet becomes coated with a monolayer of phospholipid and a cadre of proteins that stabilize it within the cytoplasm of cells (14). The growth of individual LDs within most cells results in a multilocular appearance, whereas in cells such as white adipocytes, a large unilocular droplet form. It has become evident that the regulation of LD metabolism and physiology is extremely dynamic in nature. Two recent RNAi screens in Drosophila cells uncovered a diverse array of proteins and cellular organelles that participate in LD physiology (18, 19). In all, up to 1.5% of the fly genome has been implicated in LD physiology, and proteomic analyses of LDs from yeast, mouse mammary gland, Chinese hamster ovary cells, human hepatoma cells, human squamous epithelial carcinoma cells, mouse 3T3-L1 adipocytes, fly cells, and leukocytes have revealed the existence of many LD-associated proteins, including specific marker proteins, structural proteins, enzymes involved in various aspects of cholesterol and fatty acid metabolism, and proteins that function as regulators of membrane trafficking (20–32).

A critical catalyst in our understanding of LD biology came with the identification of the first LD-associated protein, perilipin 1 (PLIN1). PLIN1 was discovered during an experiment in which adipocytes were incubated with radiolabeled 32P to label the cellular pool of ATP. When the adipocytes were treated with catecholamines to activate cAMP and cAMP-dependent PKA, autoradiogram analysis showed a protein that contained more than 95% of all the 32P (33). This protein was named “perilipin” because both

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2011;121(6):2102–2110. doi:10.1172/JCI46069.
cell fractionation and immunohistochemical studies demonstrated that it localized, in the absence and presence of PKA activation, specifically at the surface of LDs. Tissue surveys revealed that PLIN1 is most highly expressed in adipocytes and to a lesser extent in steroiodogenic tissues (34). Cloning of the cDNA for Plin1 identified a major isoform, perilipin A (35), although other isoforms are expressed at lower levels (35, 36). In silico analysis revealed four additional LD-associated proteins with homology to the N-terminal region of Plin1: ADRP (also referred to as Plin2), TIP47 (Plin3), S3–12 (Plin4), and OXPAT (Plin5). These constitute the perilipin/ADRP/TIP47 (PAT) family, which is conserved in a variety of organisms, from slime mold to mammals (36, 37). In this review we will focus on PLIN1, which is the most abundant and most thoroughly studied PAT protein in adipocytes (38–42), and on PLIN2 because of the number of studies investigating it in hepatic steatosis. One hallmark of LD proteins is that, in general, they associate with LDs in response to lipid loading of cells (43–45). However, LD proteins may have differential affinities for LDs. Plin1 actually competes with Plin2 for localization on the droplet, thereby preventing Plin2 from associating with the LD and causing Plin2 to be degraded (38, 40). Finally, droplets may also be heterogeneous and contain various combinations of the PAT proteins (46).

Dynamic interactions between Plin1 and other proteins that regulate lipolysis have been uncovered over the last several years. As we noted before, alterations in lipolysis can be detrimental to systemic metabolism. Hydrolysis of stored TAG to glycerol and fatty acids requires the sequential actions of adipose triglyceride lipase (ATGL) to hydrolyze TAG to diacylglycerol, hormone-sensitive lipase (HSL) to hydrolyze diacylglycerol, and monoacylglycerol lipase to hydrolyze monoacylglycerol to fatty acids and glycerol (47). ATGL is associated with the LD surface, perhaps because of its patatin protein domain, and bound to the G0S2 protein, which inhibits its hydrolytic activity (48). The protein CGI-58 is associated with the LD under basal conditions and can associate with ATGL and increase its catalytic activity by up to 20-fold (49). While a small amount of HSL may be associated with the LD in the absence of PKA activation, HSL is predominately located in the cytoplasm (50, 51). Monoacylglycerol lipase is thought to be constitutively activated in the absence of any phosphorylation. In the absence of PKA activation, Plin1 appears to reduce lipolysis by binding and sequestering CGI-58 and, possibly, a small amount of HSL on the droplet (51–53). Basal levels of lipolysis are predominately due to constitutive actions of ATGL (54, 55). PKA activation hyperphosphorylates Plin1, resulting in the release of CGI-58, which then binds to and increases ATGL hydrolytic activity on the droplet (52, 53). Thus, a reduction in Plin1 would result in release of CGI-58, thereby allowing it to bind ATGL, increasing the catalytic activity of ATGL and accelerating the first step of lipolysis. Additionally, PKA phosphorylation of HSL causes the protein to translocate to the LD surface, where it binds hyperphosphorylated Plin1 and preferentially hydrolyzes diacylglycerol. There are likely other potential mechanisms and factors that regulate lipolysis. In this review we will discuss how several of these proteins are dysregulated in human disease.

Like the PAT proteins, the CIDE family of proteins also associates with and regulates LD physiology. The CIDE family consists of three proteins: Cidea, Cideb, and Cidec (also referred to as fat-specific protein 27 [FSP27]). The N-terminal region of the CIDE proteins shares homology with the two-subunit proteins of DNA fragmentation factor, which is involved in apoptosis (56). Additionally, the Cide proteins have regions of homology with PLIN1, including a hydrophobic domain thought to be important for binding to the phospholipid monolayer of the droplet (57). Cidec was the first of this family to be identified as an LD-associated protein (58, 59). Subsequently, similar to PAT proteins, ectopic expression of Cide proteins promotes LD formation and reduces TAG hydrolysis (57, 60, 61). Relevant to their homology to proteins associated with apoptosis, ectopic expression of CIDE members enhances rates of apoptosis. However, when CIDE-expressing cells are incubated with oleic acid to promote TAG storage and LD formation, the rates of apoptosis are significantly reduced, presumably because sequestration of the Cide proteins on the droplets blocks their proapoptotic function (60). Cidea in lean mice is expressed predominately in brown adipose tissue (BAT), but not in white adipose tissue (WAT) (62). Cidec in mice is predominately expressed in WAT, but has also been found in BAT (62–64) and lipid-laden hepatocytes (6, 56). In humans, the expression pattern is slightly different, with both CIDE and CIDEA highly expressed in white adipocytes (57, 65).

Role of LD proteins in obesity-associated insulin resistance, diabetes, and lipoatrophic diabetes

LD proteins in lipoatrophic diabetes. Plin1 and members of the PAT family are critical regulators of lipid metabolism. In obesity, insulin resistance has been linked to increased rates of adipocyte lipolysis (1, 3, 66, 67) and increased expression of cytokines such as TNF-α. One of the first clues in elucidating Plin1 function was the observation that TNF-α reduces Plin1 mRNA and protein expression while concomitantly increasing basal lipolysis (68). Constitutive overexpression of Plin1 in cultured adipocytes blocks the ability of TNF-α to increase lipolysis, confirming a role for PLIN1 expression in regulating basal or constitutive lipolysis (69). Critical insights into the role of PLIN1 in systemic metabolism were demonstrated when two separate laboratories independently generated lines of Plin1-null mice; both groups observed that the mice were lean and developed systemic insulin resistance as they got older (70, 71). Studies comparing lipolysis in Plin1-null and wild-type mice revealed that Plin1-null adipocytes had increased rates of constitutive (unstimulated) lipolysis and reduced catecholamine-stimulated lipolysis (70). In these cells, Plin2 replaced Plin1 protein on the LD, which suggests that Plin2 is less efficacious in blocking basal adipocyte lipolysis (70, 72). Nelfinavir, an anti-HIV drug, has been reported to promote lipodystrophy in humans (73), and we demonstrated that it specifically enhanced Plin1 degradation by a lysosomal pathway in mouse adipocytes, resulting in increased rates of constitutive basal lipolysis. These data demonstrate that Plin1 protein enhances catecholamine-stimulated lipolysis and, importantly, that a reduction in Plin1 protein expression is associated with increased constitutive lipolysis, which can promote systemic insulin resistance. Recently, three individuals were reported to have one of two different heterozygous missense mutations in PLIN1, which altered the amino acids in the carboxy terminus of the protein. When ectopically expressed in cells, these mutant proteins were found to have reduced ability to block TAG hydrolysis, leading to increased rates of constitutive lipolysis as compared with wild-type PLIN1 (74). These subjects had partial lipodystrophy, with loss of adipose tissue in their femorogluteal region and lower limbs, along with Cushingoïd or acromegaloïd features, insulin-resistant diabetes, hypertriglyceridemia and hepatic steatosis.
Similar to Plin1, TNF-α treatment of mouse adipocytes reduces Cidec expression, and siRNA knockdown of Cidec increases rates of basal constitutive lipolysis, whereas overexpression of Cidec blocks the effect of TNF-α on lipolysis (57–60, 65, 75, 76). Two separate laboratories generated Cidec-knockout mice (63, 64). Cidec-knockout mice have features similar to those of Plin1-null mice, such as reduced fat mass and increased lipolysis (63). The knockout animals have increased energy expenditure and are protected against the development of genetic or diet-induced obesity (70, 71). Basal lipolysis is increased in isolated white adipocytes from Cidec-null mice, and catecholamine-stimulated lipolysis is reduced (63). However, unlike Plin1-null mice, Cidec-null mice are protected against the development of diet-induced insulin resistance. One human patient has been described as having a homozygous nonsense mutation in the CIDEC gene that resulted in a truncated protein that was unable to associate with LDs (77). This patient had partial lipodystrophy with absence of femorogluteal and lower-limb adipose tissue, along with insulin-resistant diabetes, hypertriglyceridemia, and hepatic steatosis (see Figure 1). The mechanism by which Cidec blocks basal lipolysis remains poorly understood and is a goal of future research studies. Thus, loss of PLIN1 or CIDEA expression in humans, unlike mice, results in ectopic lipid accumulation, dyslipidemia, and diabetes.

Besides the increase in adipocyte lipolysis which reduces TAG content in adipocytes, the constitutive lipolysis induced by a reduction in either Plin1 or Cidec also reduces fat mass by activating fat oxidation pathways. For example, fatty acids from lipolysis can directly activate transcription factors such as PPARα to promote fat oxidation (78, 79). Additionally, lipolysis in white adipocytes can activate AMP-activated protein kinase, which also promotes fat oxidation and reduces lipogenesis (80). In both Cidec- and Plin1-null mice, oxidative gene expression is increased in WAT (63, 64, 81, 82). Furthermore, in Cidec-null mice, uncoupling protein 1 (UCP1) expression is increased in WAT, endowing it with characteristics of brown adipocytes such as multilocular LDs and enhanced thermogenesis (64). Thus, with reduced expression of LD proteins and increased lipolysis, fatty acids can promote fat oxidation. However, this compensatory pathway is not sufficient to prevent the detrimental release of fatty acids and subsequent development of insulin resistance, at least in Plin1-null mice. Potentially, differences in rates of constitutive lipolysis and fat oxidation in adipocytes may at least in part explain the differential susceptibility of Plin1- and FSP27/Cidec-null mice to insulin resistance. Of potential relevance is our observation that overexpressing human or mouse Plin1 in female mice protects against the development of obesity and obesity-associated insulin resistance while increasing expression of oxidative genes in adipose tissue (83, 84). Overexpression of Plin1 potently reduces expression of FSP27 in adipocytes, which may partly explain the protection against obesity and insulin resistance. In summary, a significant reduction in LD proteins may promote both lipolysis and oxidative metabolism, providing another mechanism to reduce adipose mass.

While BAT has recently emerged as being present in humans, its role in regulating adult metabolism is unclear (85). In mice, BAT contributes to the regulation of body adiposity and thermogenesis. Similar to WAT, brown adipocytes store TAG and, in response...
to locally released norepinephrine, undergo PKA-activated lipolysis. However, brown adipocytes express UCPI, which uncouples the generation of ATP from fat oxidation, resulting in the generation of heat. Fatty acids released by lipolysis directly activate UCPI. Ablation of the Chipa gene in mice, which is predominately expressed in BAT in mice, results in increased BAT lipolysis, temperature, metabolic rate, and a reduction in respiratory exchange ratio consistent with increased fat oxidation (62). Additionally, the presence of Chipa promotes degradation of the AMPK β subunit (86), reducing AMPK activation, which may also contribute to reduced oxidative metabolism and protection against diet-induced obesity. Brown adipocytes also express Plin1. In recent studies using lines of transgenic and Plin1-knockout mice, we demonstrated that the mutation of the six consensus PKA sites of Plin1 from serine to alanine blocked catecholamine-stimulated lipolysis (86), reducing AMPK activation, which may also contribute to reduced oxidative metabolism and protection against diet-induced obesity. Several studies have found that polymorphisms in the PLIN1 (101–107) and CIDE (108, 109) genes influence body weight and the risk of metabolic disease. Interestingly, one PLIN1 polymorphism was found to be associated with reduced PLIN1 expression and increased rates of basal and stimulated adipocyte lipolysis (95). Consistent with the increased rates of lipolysis, humans with this polymorphism tend to have reduced body weight and body fat mass (106, 110). PLIN1 polymorphisms have also been suggested to affect the ability to lose weight on a diet (101, 103), as well as the metabolic response to exercise (111). More work is needed to confirm and extend these observations among different human populations.

Role of LDs in non-alcoholic fatty liver disease and nonalcoholic steatohepatitis

In obese humans, nonalcoholic fatty liver disease (NAFLD) is becoming more prevalent (112, 113) and can lead to nonalcoholic steatohepatitis (NASH), cirrhosis, and even cancer (114). Hepatic steatosis is often associated with resistance to the actions of insulin on hepatic gluconeogenesis, while hepatocytes remain sensitive to the lipogenic actions of insulin (115). In obesity, fatty acids released from adipocytes are an important source of fatty acids that are found as TAG within hepatic LDs (116). There are a limited number of papers that have investigated the role of LD proteins in human liver, with the greatest number focusing on the PAT proteins. In normal liver both PLIN2 and PLIN3 have been found to be associated with LDs (46). However, with the development of hepatic steatosis, PLIN1 protein is found localized to hepatocyte LDs (46). Consistent with this histologic observation, two separate studies, which used microarray analysis to determine the expression pattern of proteins in NAFLD, revealed PLIN1 as one of the most prominent upregulated genes (117, 118). Interestingly, in steatotic hepatocytes, the pattern of PLIN1, -2, and -3 proteins differ depending upon the size of the LDs and their intracellular localization (46). In a second study, the association of PLIN1 and PLIN2 with LDs were observed in subjects with both NAFLD and NASH (119). PLIN1 tended to be associated with larger LDs, while expression of PLIN2 was more correlated with the presence of ballooned hepatocytes and evidence of oxidation (119). The possible significance and differing roles of PLIN1 and -2 in liver disease is an important unanswered question.

The liver contains several lipases, including ATGL, HSL, TAG lipase (120), and a related lipase called “PNLPA3” (ref. 121; Figure 2). In a genome-wide scan, mutations in PNPLA3 were associated with an increased risk of NAFLD in Hispanics and reduced risk in African Americans (121). PNPLA3 was identified as a LD protein that hydrolyzes TAG (122). More recently a missense mutation

Role of CIDE/PLIN1 in obese animals and humans

Obese individuals have reduced expression of CIDEA in their adipocytes, which appears to correlate with features of the metabolic syndrome (65). Interestingly, knockdown of CIDEA in human adipocytes increases both lipolysis and the expression of TNF-α, a cytokine implicated in the development of obesity-associated insulin resistance. One study reported that PLIN1 mRNA and protein expression was reduced in adipocytes in morbidly obese men and women (93), although another laboratory found that PLIN1 expression increases with obesity (94). Other investigators have linked levels of PLIN1 expression in adipocytes to rates of constitutive lipolysis (95), an observation that is consistent with a reduction of PLIN1 with obesity. Obese animals have also been found to have dramatically reduced expression of Plin1 (96). A recent study investigated whether expression of PLIN1, CIDEA, and CIDEC differed in obese individuals based on insulin sensitivity. Importantly, the expression of PLIN1, CIDEA, and CIDEC is reduced in both subcutaneous and omental adipose tissue of insulin-resistant individuals compared with weight-matched insulin-sensitive individuals (57). Presumably, the individuals with reduced expression of these LD proteins had increased adipocyte lipolysis that resulted in increased levels of circulating fatty acids and insulin resistance (Figure 1). Particularly relevant in this regard, as we noted previously, TNF-α reduces expression of PLIN1 (68, 97) and CIDEC (75, 76) in adipocytes, while enhancing PKA activation in human adipocytes (98) and increasing fatty acid release. Treatment with thiazolidinediones blocks TNF-α–induced lipolysis in part by blocking the decrease in Plin1 expression (68). Of further relevance to these observations is that fatty acids can activate inflammatory pathways by engaging TLRs on cells. Increased rates of lipolysis have been linked to recruitment of macrophages in adipose tissue (refs. 99, 100; Figure 1). Together these observations provide a mechanistic framework linking two hallmarks of obesity that are implicated in the development of obesity complications, i.e., adipose tissue inflammation and fatty acid flux.

Several studies have found that polymorphisms in the PLIN1 (101–107) and CIDE (108, 109) genes influence body weight and the risk of metabolic disease. Interestingly, one PLIN1 polymorphism was found to be associated with reduced PLIN1 expression and increased rates of basal and stimulated adipocyte lipolysis (95). Consistent with the increased rates of lipolysis, humans with this polymorphism tend to have reduced body weight and body fat mass (106, 110). PLIN1 polymorphisms have also been suggested to affect the ability to lose weight on a diet (101, 103), as well as the metabolic response to exercise (111). More work is needed to confirm and extend these observations among different human populations.
(L148M) in PNPLA3 was associated with increased risk of developing NAFLD. Importantly, in vitro studies revealed that this mutation in PNPLA3 ablated the ability of the protein to hydrolyze TAG (122). However, it is important to note that PNPLA3-knockout mice do not develop hepatic steatosis (123), which suggests that the PNPLA3 mutants identified in humans might interfere with other proteins involved in normal hepatic LD metabolism.

While we have limited knowledge of how PLIN2 accumulation regulates the accumulation of TAG in hepatocytes of humans, most of our knowledge about the in vivo role of these LD proteins is inferred from studies in rodents. Plin2 and Plin3, but not Plin1, are generally associated with hepatic LDs of rodents. More recently we found that addition of alcohol to a high-fat diet resulted in expression of both Plin1 and Plin2 and hepatocyte LD (124), but the importance and mechanisms that result in Plin1 expression here are unclear. Loss of Plin2 expression in mice reduced the effect of high-fat diet–induced liver TAG accumulation (125). When the Plin2-knockout mice were crossed with ob/ob mice, the insulin resistance of the double-knockout mice improved in both the liver and skeletal muscle (126). In ob/ob/Plin2-null mice, liver fat accumulation was reduced by 25%, perhaps secondary to increased VLDL secretion. With loss of Plin2, Plin3 became associated with the LDs, while Plin5 expression was greatly increased. Knockout or knockdown of Plin2 in the liver reduces hepatic TAG levels in both genetic and diet-induced obese mice and improves hepatic insulin sensitivity (125–128). The increased insulin sensitivity in mice with reduced or ablated Plin2 might be explained by reduced hepatic diacylglycerol content (128, 129).

Previous studies had suggested that one mechanism by which Plin2 expression reduces lipid hydrolysis was that it excludes ATGL from the droplet (130). In support of this observation, overexpression of Plin2 significantly decreases TAG hydrolysis in hepatocytes, while siRNA knockdown of Plin2 or overexpression of ATGL enhances TAG hydrolysis (131). Interestingly, altering TAG hydrolysis through manipulations of Plin2 or ATGL regulates PPARα activity and target gene expression. Specifically, ATGL overexpression and Plin2 knockdown activate PPARα, whereas Plin2 overexpression inhibits PPARα activity and fat oxidation (128, 131). Plin2 ablation may reduce hepatic TAG and increase insulin sensitivity in obese mice by several mechanisms. In contrast, combined knockdown of both Plin2 and Plin3 in cultured hepatocytes exposed to fatty acids results in significantly increased insulin resistance (132). In summary, reduction of Plin2 promotes a reduction in hepatic steatosis and increases insulin sensitivity, but a reduction in both Plin2 and Plin3 causes insulin resistance.

The CIDE proteins are also expressed on hepatocyte LDs when the liver accumulates TAG, such as in ob/ob mice (6). In hepatocytes, the transcription factor PPARγ increases Cidec expression (6), and SREBP1 regulates Cidea (133). Adenovirus-mediated overexpression of Cidec in liver increases TAG accumulation in lean mice, whereas knockdown of FSP27 in ob/ob mice reduces hepatic TAG accumulation (6). In mice, Cidec is predominately expressed in liver, less expressed in kidney, and expressed very little in small intestine and colon. Cidec is thought to be associated both with the endoplasmic reticulum and LDs (61). Cideb-knockout mice are protected against diet-induced obesity, have increased fat oxidation, and are...
insulin sensitive (134). Cideb within the liver is necessary for the acquisition of TAG and apoB binding in the developing VLDL particle (61). Thus the CIDE proteins have an important but not completely understood role in hepatic LD metabolism.

**LDs and skeletal muscle metabolism**

Our understanding of the role of LDs in regulating metabolism in skeletal muscle is less well developed, and a function of PAT proteins in regulating insulin action in skeletal muscle of obese and diabetic individuals has not been well delineated. Studies conflict as to whether the level of PLIN2, or possibly PLIN5, is related to insulin resistance in obese, diabetic individuals (135, 136). Tissue-specific ablation of Plin2 and -5 in skeletal muscle will provide important insights into their actions. In certain states, skeletal muscle can store increased amounts of TAG in LDs, which correlates with insulin resistance (137). Intriguingly, SNARE proteins such as SNAP23 are required for both LD fusion (138) as well as insulin-mediated vesicular trafficking of Glut4 to the plasma membrane. When muscle cells were incubated with oleic acid, a complement of SNAP23 proteins appeared to be diverted from the plasma membrane to the surface of the newly formed LDs (138). SNAP23 sequestration on LDs of oleic acid–treated cells was coincident with attenuated insulin-stimulated glucose transport. Moreover, consistent with these in vitro observations, more SNAP23 was localized to the non-plasma membrane pool in muscle cells of type 2 diabetics in whom intracellular lipid was increased (139).

Mutations in genes involved in LD turnover have been linked to lipid storage disease and myopathy in humans. Mutations in ATGL result in a form of neutral lipid storage disease with myopathy that is manifest by TAG accumulation in skeletal and cardiac muscle, liver, and leukocytes (140–142). Other than myopathy, metabolic manifestations have been variable, with most patients having normal glucose and lipid levels (140–142). Mutations in CGI-58 also result in neutral lipid storage disease (Chanarin-Dorfman syndrome) and are associated with ichthyosis (143, 144). Thus, there are TAG droplets observed in skin, liver, and leukocytes. No mutations have yet been described in other genes involved in LD hydrolysis, such as HSL.

The import of these LDs is that the muscle of elite athletes contains high amounts of myofibrillar PKC isozymes that promote insulin resistance. Muscles from these transgenic mice also have increased fatty acid oxidation (148). The observation that DGAT overexpression promotes the formation of TAG without causing insulin resistance has been replicated in other tissues besides muscle. Overexpressing DGAT in liver results in hepatic steatosis but does not cause insulin resistance (149). One line of Dgat1 transgenic mice in which Dgat1 was overexpressed in both adipocytes and macrophages or in macrophages alone was protected against diet-induced insulin resistance (150, 151). Furthermore, overexpression of Dgat1 in heart protects against cardiac lipotoxicity (152). These data underscore the importance to metabolic health of sequestering excess free fatty acids in esterified form (TAG) within LDs.

**Conclusion**

All cells can form and sequester neutral lipids within LDs, especially when exposed to increased levels of fatty acids. At present, it is evident that proteins in the PAT and CIDE families can facilitate the storage of fatty acids within LDs and reduce rates of hydrolysis. However, these LD-associated proteins differ in their ability to modulate lipid hydrolysis. Our appreciation of the multiple physiologic and pathophysiologic roles of LDs continues to evolve, with LDs now recognized as important regulators of atherosclerosis (153, 154), cancer (155), and viral replication (156). It is exciting that we are just beginning to appreciate the full complexity and importance of LD metabolism. Greater understanding of LD biogenesis, composition, and heterogeneity will provide new insights in understanding the role of LDs in health and disease.

**Acknowledgments**

This work was supported by grants from the American Diabetes Association (7-08-RA-57 to A.S. Greenberg; 7-07-JF-43 to D.G. Mashek), the USDA Agricultural Research Service (58-1950-7-707 to A.S. Greenberg), the Department of Veterans Affairs Office of Research and Development Medical Research Service (to F.B. Kraemer) and the NIH (AG028098 to F.B. Kraemer; DK082257, 1R25ES018781, and R24DK087669 to A.S. Greenberg; DK56598 and DK59935 to R.A. Coleman; RO1-HD045962 and PO1-HD38129 to J.L. McManaman; 3P30DK046200 to V. Puri; DK074979 to M.S. Obin; and DK085008 to D.G. Mashek). The Obesity Review Series is supported in part by unrestricted educational grants from Merck & Co. and the Life Sciences Institute of the University of Michigan.

Address correspondence to: Andrew S. Greenberg, Tufts University, 711 Washington Street, Boston, Massachusetts 02111, USA. Phone: 617.556.3144; Fax: 617.556.3224; E-mail: Andrew.greenberg@tufts.edu.


To view the full article, please visit the journal's website.


